1. Survival patterns of childhood neuroblastoma: an analysis of clinical data from Southern-Eastern European countries
- Author
-
Helen Dana, Maria A. Karalexi, Paraskevi Panagopoulou, Emmanuel Hatzipantelis, Maria Kourti, Panagiota Bouka, Marios Themistocleous, Vassilios Papadakis, Evangelia E. Ntzani, Denis Kachanov, Astero Malama, Maria Moschovi, Kalliopi Stefanaki, Eleni Petridou, Margaret Baka, T.V. Shamanskaya, Marina Servitzoglou, Maria Kantzanou, Nick Dessypris, Sofia Polychronopoulou, Maja Česen Mazič, Katerina Strantzia, and Eftichia Stiakaki
- Subjects
Cancer Research ,medicine.medical_specialty ,Epidemiology ,business.industry ,Hazard ratio ,Public Health, Environmental and Occupational Health ,Cancer registration ,Confidence interval ,Eastern european ,Oncology ,Internal medicine ,medicine ,Surgical excision ,Risk of death ,Stage (cooking) ,Childhood Neuroblastoma ,business - Abstract
The prognosis of children with neuroblastoma (NBL) can be dismal with significant variations depending on the stage and biology of the tumor. We assessed the event-free (EFS) and overall (OS) survival using harmonized data from three Southern-Eastern European (SEE) countries. Data for 520 incident NBL cases (2009-2018) were collected from Greece, Slovenia and Russia. Kaplan-Meier curves were fitted, and EFS/OS were derived from Cox proportional models by study variables including the protocol-based risk-group (low/observation, intermediate, high). Over one-third of cases were coded in the high-risk group, of which 23 children (4.4%) received treatment with anti-ganglioside 2 (GD2) mAb. Survival rates were inferior in older (OS 5-year; 1.5-4.9 years: 61%; EFS 5-year; 1.5-4.9 years: 48%) compared to children younger than 1.5 years (OS 5-year
- Published
- 2020